Discover
ATRA
Atara Biotherapeutics, Inc.
9.69
2 x 7.18
2 x 12.31
bid
ask
-
0.02
0.21%
2 @ 04:10 PM
9.69 +0.00 (0.00%)
| Ytd | -46.43% | |
| 1y | -19.72% |
9.60
day range
10.19
4.18
52 week range
18.09
| Open | 10.18 | Prev Close | 9.71 | Low | 9.60 | High | 10.19 | Mkt Cap | 97.27M |
| Vol | 37.77K | Avg Vol | 61.69K | EPS | -1.54 | P/E | N/A | Forward P/E | -1.52 |
| Beta | 0.49 | Short Ratio | 7.11 | Inst. Own | 50.82% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 8.93 | 200-d Avg | 8.64 | 1yr Est | 16.33 |
| Income Statement | |||
| Total Revenue | 630.00K | ||
| Revenues (USD) | 630.00K | ||
| Cost of Revenue | 191.00K | ||
| Gross Profit | 439.00K | ||
| Operating Expenses | 5.16M | ||
| Research and Development Expense | 1.35M | ||
| Selling, General and Administrative Expense | 3.81M | ||
| Operating Income | -4.72M | ||
| Interest Expense | 191.00K | ||
| Income Tax Expense | 1000 | ||
| Net Income | -4.83M | ||
| Net Income Common Stock | -4.83M | ||
| Net Income Common Stock (USD) | -4.83M | ||
| Consolidated Income | -4.83M | ||
| Earnings per Basic Share | -0.32 | ||
| Earnings per Basic Share (USD) | -0.32 | ||
| Earnings per Diluted Share | -0.32 | ||
| Earning Before Interest & Taxes (EBIT) | -4.64M | ||
| Earning Before Interest & Taxes (USD) | -4.64M | ||
| Weighted Average Shares | 15.03M | ||
| Weighted Average Shares Diluted | 15.03M | ||
| Balance Sheet | |||
| Cash and Equivalents | 3.22M | ||
| Cash and Equivalents (USD) | 3.22M | ||
| Investments | 6.65M | ||
| Investments Current | 6.65M | ||
| Trade and Non-Trade Receivables | 318.00K | ||
| Current Assets | 13.53M | ||
| Property, Plant & Equipment Net | 6.73M | ||
| Total Assets | 21.02M | ||
| Debt Current | 1.03M | ||
| Total Debt | 50.32M | ||
| Current Liabilities | 6.85M | ||
| Debt Non-Current | 49.29M | ||
| Total Liabilities | 58.02M | ||
| Accumulated Retained Earnings (Deficit) | -2.03B | ||
| Accumulated Other Comprehensive Income | -2.00K | ||
| Shareholders Equity | -37.00M | ||
| Shareholders Equity (USD) | -37.00M | ||
| Assets Non-Current | 7.49M | ||
| Total Debt (USD) | 50.32M | ||
| Deferred Revenue | 775.00K | ||
| Liabilities Non-Current | 51.17M | ||
| Trade and Non-Trade Payables | 824.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 205.00K | ||
| Net Cash Flow from Financing | 4.83M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -5.14M | ||
| Issuance (Purchase) of Equity Shares | 4.83M | ||
| Net Cash Flow from Investing | -6.63M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -6.63M | ||
| Net Cash Flow from Operations | -3.34M | ||
| Share Based Compensation | 394.00K | ||